Intellectual Property Section: What It Reveals About a Tech Company's Moat in Hong Kong

The market for Hong Kong-listed technology companies has entered a period where patent portfolios and trade secret regimes determine valuation multiples as directly as revenue growth. The SFC’s 2024-25 thematic review of IPO prospectuses flagged intellectual property (IP) disclosures as a recurring deficiency, with 43% of reviewed technology issuer filings containing material omissions regarding patent expiry timelines or licensing dependencies (SFC, Thematic Review of IPO Prospectus Disclosures, December 2024). Simultaneously, the HKEX’s proposed amendments to the Listing Rules, effective Q1 2026, will mandate enhanced IP risk factor disclosure for issuers on the Main Board under Chapter 9. For analysts and underwriters, the IP section of a prospectus is no longer boilerplate — it is the single most reliable indicator of whether a company possesses a genuine technological moat or merely a temporary first-mover advantage. This article examines what the IP section reveals, how to read it with regulatory precision, and what recent listing documents from the HKEX’s GEM and Main Board tell us about the quality of disclosed moats.

The Regulatory Framework: What HKEX and the SFC Require

Listing Rule Chapter 9 and the New IP Disclosure Mandate

HKEX Listing Rule 9.10(2)(g), as amended in the December 2025 consultation conclusions, now explicitly requires that a listing document for a technology issuer on the Main Board include a dedicated section on intellectual property. This section must contain: (i) a complete schedule of registered patents, trademarks, and design rights held by the issuer and its subsidiaries, with jurisdiction and expiry dates; (ii) a description of material unregistered IP, including trade secrets and know-how, with an explanation of how the issuer maintains confidentiality; and (iii) a risk factor analysis addressing the likelihood of third-party infringement, the issuer’s own freedom-to-operate status, and any pending or threatened litigation. The rule applies to all new listing applications submitted after 1 April 2026. For GEM issuers, the equivalent requirement appears under GEM Rule 11.10(2)(g), with a reduced but still substantive disclosure standard.

The SFC’s 2024 Thematic Review: Common Deficiencies

The SFC’s review identified three recurring gaps in IP disclosures among technology issuers. First, 31% of reviewed prospectuses failed to disclose material patent licence agreements that were subject to termination clauses tied to change-of-control events — a critical omission for IPO investors. Second, 22% of issuers did not adequately describe the geographic scope of their patent protection, leaving ambiguity about whether key patents covered only the PRC or extended to the US, EU, or ASEAN jurisdictions. Third, 14% of documents omitted any discussion of trade secret protection measures, despite the issuer’s business model relying heavily on proprietary algorithms or manufacturing processes. The SFC explicitly warned that such omissions could constitute a breach of the Code on Takeovers and Mergers (SFC, Thematic Review, 2024, para. 3.12) if they materially mislead investors about the issuer’s competitive position.

Deconstructing the IP Section: What to Look For

Patent Portfolio Quality: Quantity vs. Duration vs. Jurisdiction

A common trap for analysts is equating a large patent count with a strong moat. The IP section of a prospectus typically lists the number of granted patents and pending applications. The critical data points are not the totals but the median remaining life of granted patents and the geographic distribution of filings. For a Hong Kong-listed technology company, a patent portfolio with a median remaining life of less than five years — absent a clear pipeline of replacement patents — signals that the issuer’s core technology protection is expiring. In the 2025 prospectus of Horizon Robotics (stock code: 9660.HK), the company disclosed 1,247 granted patents but with a weighted average remaining life of 4.3 years across its autonomous driving portfolio. The prospectus also revealed that 78% of these patents were PRC-only, with only 12% having corresponding US filings. For an issuer targeting global automotive OEMs, this geographic concentration represents a material risk that the IP section itself highlighted — a rare instance of transparent disclosure.

Licensing-In Dependency: The Hidden Leverage Point

Many Hong Kong-listed technology companies, particularly those in semiconductor design and biotech, operate under inbound licence agreements from third-party patent holders. The IP section must disclose the key terms of these licences, including exclusivity, territory, field-of-use restrictions, and termination rights. The most important clause to examine is the change-of-control provision. Under HKEX Listing Rule 9.10(2)(g)(iii), the issuer must state whether any material licence agreement contains a clause that would allow the licensor to terminate or renegotiate the licence upon a change of control of the issuer. In the 2024 prospectus of QuantumPharm (stock code: 2228.HK), the company disclosed that its core AI drug discovery platform relied on a non-exclusive licence from a US university, which could be terminated with 90 days’ notice if the issuer underwent a change of control. This clause effectively capped the company’s acquisition premium and was flagged as a material risk factor — a disclosure that the SFC would consider compliant but that investors should treat as a significant warning.

Trade Secrets and Know-How: The Invisible Moat

For software and AI companies, patents may be less relevant than trade secrets. The IP section should describe the issuer’s measures to protect confidential information, including employee confidentiality agreements, access controls, and data encryption standards. The SFC’s 2024 review noted that issuers in the AI sector frequently omitted any discussion of trade secret protection, relying instead on a generic statement that “the company maintains confidentiality procedures.” The SFC considers this insufficient. A compliant disclosure should specify the number of employees with access to core algorithms, the frequency of internal audits, and whether the issuer has ever experienced a data breach or theft of trade secrets. In the 2025 prospectus of SenseTime Group (stock code: 0020.HK), the company disclosed that its core facial recognition algorithms were protected under a three-tier access system, with fewer than 50 employees holding full access rights, and that the company conducted quarterly internal audits — a level of granularity that the SFC would view favourably.

Cross-Border IP Structuring: The Hong Kong-Listed Issuer’s Dilemma

The Cayman-BVI-Hong Kong-PRC Chain and IP Ownership

Most Hong Kong-listed technology companies are incorporated in the Cayman Islands, with a BVI intermediate holding company and a PRC operating entity under a VIE or direct ownership structure. The IP section must clearly identify which entity in this chain owns the registered patents and trade secrets. A common structure involves the PRC subsidiary holding the PRC patents, while the Cayman parent holds the international filings. This creates a jurisdictional risk: if the PRC subsidiary is subject to a national security review under the PRC Cybersecurity Law (2017) or the Data Security Law (2021), the parent’s ownership of the IP may be challenged. The HKEX Listing Rules require disclosure of any such risks under Chapter 9.10(2)(g)(iv). In the 2024 prospectus of Kingdee International Software Group (stock code: 0268.HK), the company explicitly stated that its core cloud computing patents were held by its PRC subsidiary, and that any regulatory action against that subsidiary could impair the group’s ability to use its own IP — a disclosure that the SFC would consider prudent.

VIE Structures and IP Enforcement Risk

For issuers using variable interest entity (VIE) structures, the IP section must address the enforceability of the VIE agreements with respect to IP. Under PRC law, a VIE agreement is a contractual arrangement that purports to give the Cayman parent economic control over a PRC operating company. However, the PRC Civil Code (2020) and subsequent judicial interpretations have cast doubt on the enforceability of certain VIE provisions, particularly those involving the transfer of IP rights. The HKEX requires that the IP section disclose whether the VIE agreements have been tested in a PRC court and whether the issuer has obtained a legal opinion from PRC counsel on enforceability. In the 2025 prospectus of Meituan (stock code: 3690.HK), the company disclosed that it had obtained a PRC legal opinion confirming the enforceability of its VIE agreements, subject to certain limitations under the Foreign Investment Law (2020). This level of disclosure is the minimum standard that the SFC expects.

Case Studies: What Three Recent Hong Kong IPOs Reveal

Case Study 1: A Biotech Issuer with a Concentrated Patent Portfolio

In December 2024, a Hong Kong-listed biotech company (stock code: 2555.HK) filed its prospectus with a patent portfolio consisting of 23 granted patents and 47 pending applications. The IP section disclosed that 18 of the 23 granted patents were for a single drug candidate, and that these patents had a weighted average remaining life of 3.1 years. The company also disclosed that its lead drug candidate was licensed from a US university under an exclusive agreement that could be terminated if the issuer failed to achieve certain development milestones. The SFC’s review of this prospectus — conducted as part of its thematic review — found that the IP section was compliant but that the concentrated nature of the portfolio constituted a material risk that should have been more prominently flagged. The SFC did not require a resubmission, but it issued a private observation to the sponsor. For analysts, this case illustrates that a small, concentrated patent portfolio with short remaining life is a clear sign of a weak moat, regardless of the issuer’s revenue projections.

Case Study 2: A Semiconductor Issuer with a Strong Trade Secret Regime

In March 2025, a Hong Kong-listed semiconductor design company (stock code: 3666.HK) filed its prospectus with a focus on trade secrets rather than patents. The IP section disclosed that the company had zero granted patents but had developed a proprietary chip architecture protected under a comprehensive trade secret programme. The disclosure included: (i) a description of the company’s physical and digital access controls, including biometric authentication and air-gapped servers; (ii) the number of employees with access to the core architecture (12); (iii) the frequency of internal audits (monthly); and (iv) a statement that the company had never experienced a theft of trade secrets. The SFC’s review found this disclosure to be exemplary and noted it in its thematic review as a model for other issuers. For investors, the absence of patents was not a red flag because the trade secret regime was robust and transparently disclosed. This case demonstrates that a strong moat can exist without a large patent portfolio, provided the issuer is willing to disclose the details of its protection measures.

Case Study 3: A Fintech Issuer with Cross-Border IP Risks

In June 2025, a Hong Kong-listed fintech company (stock code: 1888.HK) filed its prospectus with a complex cross-border IP structure. The company’s core payment processing algorithm was patented in the PRC (under the PRC Patent Law, 2020 revision) and in Hong Kong (under the Patents Ordinance, Cap. 514), but not in the US or EU. The IP section disclosed that the company had filed for US patent protection but that the application was still pending and faced potential rejection due to prior art. The company also disclosed that its PRC subsidiary held the PRC patents, while the Cayman parent held the Hong Kong patents — a structure that created a risk of conflicting ownership in the event of a dispute. The SFC required the issuer to include a risk factor specifically addressing the possibility that the PRC subsidiary could be forced to transfer its patents to a PRC entity under the Technology Import and Export Regulations (2020). This case highlights the importance of examining not just what IP is owned, but who owns it and in which jurisdiction.

Actionable Takeaways for Analysts and Issuers

1. Examine the median remaining life of granted patents, not just the total count — a portfolio with a median life below five years indicates a rapidly eroding moat, regardless of the number of filings.

2. Identify all inbound licence agreements and read the change-of-control clauses — a termination provision tied to an IPO or acquisition can render the entire IP position worthless and should be flagged as a material risk.

3. Verify the geographic scope of patent protection against the issuer’s target markets — a company with PRC-only patents that claims a global addressable market is either overstating its moat or understating its risk.

4. Assess the trade secret regime for software and AI issuers — the absence of a detailed disclosure on access controls, employee agreements, and audit frequency is a red flag, per the SFC’s 2024 guidance.

5. Map the IP ownership chain through the corporate structure — ensure that the entity holding the core IP is in a jurisdiction with enforceable legal protections and that the VIE or direct ownership agreements have been tested by PRC counsel.